A new Nature Communications study is reshaping how scientists think about the origins of cancer-causing mutations. The research focuses on a DNA-managing enzyme called TOP2B (topoisomerase IIβ)—an essential “stress-relief” protein that helps untangle DNA so genes can be switched on. Until now, TOP2B was mostly viewed as a helpful regulator of transcription. But this new work shows something far more dramatic: TOP2B sits right at the center of many of the mutational hotspots that drive cancer.
By examining actual human tumors, the researchers mapped exactly where TOP2B binds across the genome. What they discovered is striking—the enzyme frequently marks regions where dangerous DNA events occur, including double-strand breaks, structural rearrangements, and the very mutations that push cells toward cancer. These hotspots are most common at hyper-active promoters, enhancers, and the architectural “loop anchors” that help fold DNA in 3-dimensional space.
Even more compelling, the study found that TOP2B-binding sites near major cancer genes—TP53, MYC, FOXA1, VHL, and even the non-coding driver RMRP—carry some of the highest burdens of mutations and structural variants. This strongly suggests that normal TOP2B activity, when misregulated or stressed, can unintentionally contribute to cancer genome evolution.
Why This Matters—and How TopoGEN Enables This Frontier Research
Understanding how topoisomerases create or influence mutations is becoming central to modern cancer biology. That’s why TopoGEN’s technologies are uniquely suited to advance this research. Our ICE Assays, TOP1/TOP2 cleavage-complex detection kits, and functional drug-testing platforms allow scientists to:
-
Pinpoint enzyme-mediated DNA damage
-
Quantify trapped cleavage complexes
-
Identify new therapeutic strategies targeting TOP1 and TOP2 pathways
Top2B studies like this reveal how topo-driven DNA damage shapes cancer, and TopoGEN provides the essential tools that make these discoveries—and future anti-cancer therapies—possible.
https://doi.org/10.1038/s41467-025-65005-6
#Topoisomerase #CancerGenomics #DNARepair #PrecisionOncology #DrugDiscovery #TopoGEN #ICEAssay #CancerResearch #GenomicInstability #TherapeuticInnovation